11:30 - 26.01.2022
January 26, Fineko/abc.az. The net profit of Johnson & Johnson (J&J), the world's largest manufacturer of health products, has increased 2.7 times in the 4th quarter of 2021 up to $4.736 bn, or $1.77 per share, compared with $1.738 bn, or $0.65 per share, for the same period of 2020.
According to J&J, quarterly revenue increased by 10.4% up to $24.804 bn against $22.475 bn a year earlier.
The revenue of the division that produces consumer medical products grew by 1.1% up to $2.657 bn. Revenue in the field of pharmaceutical products increased by 16.5% up to $14.29 bn, in the segment of medical devices by 4.1% up to $6.859 bn.
J&J improved forecasts of key financial indicators for 2021. According to the new forecast, the adjusted profit of the company will be $10.4-10.6 per share (previous forecast - $9.77-9.82 per share), revenue including income from the sale of vaccines against COVID-19 - $98.9-100.4 bn (previous forecast - $92.8-93.3 bn).
Analysts forecasted company's annual revenue of $98 bn, and adjusted earnings - $10.35 per share.
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
17 Апрель 2024
15 Апрель 2024
15 Апрель 2024
15 Апрель 2024
15 Апрель 2024
16 Апрель 2024